SV-102

Phase 2Small molecule

WWilliams Cancer Foundation

SV-102 is one of 57 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Metastatic Castration-Resistant Prostate CancerRecruiting

Prostate CancerPhase 1

Active, not recruiting

Metastatic Castration-Resistant Prostate CancerPhase 2

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

SV-102

WWilliams Cancer Foundation

Phase 2

1 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06533644

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Completed·WWilliams Cancer Foundation·Phase 1·NCT05544227·15 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting·SSyncromune, Inc.·Phase 2·NCT06533644·91 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SV-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SV-102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SV-102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Williams Cancer Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWilliams Cancer Foundation

SV-102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Prostate Cancer1 trial

Metastatic Castration-Resistant Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News